Mr. Sieczkarek was appointed Chairman of the Board of NovaBay in April 2015. He served as past CEO and Chairman of the Board of Solta Medical, Inc. and served as a director for seven years until it was acquired by Valeant Pharmaceuticals International, Inc. in January 2014. Mr. Sieczkarek has more than 18 years of leadership experience in the medical device industry and served as President and Chief Executive Officer of Conceptus, Inc. from 2003 to 2011. Previously, Mr. Sieczkarek was Senior Vice President and President of The Americas Region, responsible for the commercial operation of all Bausch & Lomb businesses in the United States, Canada and Latin America. Mark joined Bausch & Lomb in 1995 as Vice President and Controller in the Personal Products division and also served as a Vice President in Corporate Business Development. Previously, Mark held an executive level position with KOS Pharmaceuticals, several Bristol Myers-Squibb subsidiaries and Sanofi Diagnostics Pasteur.
Mr. Sieczkarek received a MBA degree in Finance from Canisus College in Buffalo, NY, and a B.S. degree in Accounting from the State University of New York at Buffalo.
Paul E. Freiman
Paul E. Freiman currently serves as Chairman of Penwest Pharmaceutical Co., and serves on the boards of Calypte Biomedical Corporation, NeoPharm, Inc., Otsuka America Pharmaceuticals, Inc., and SciGen Ltd. Mr. Freiman was most recently the President and CEO of Neurobiological Technologies Inc. Prior to this role, he held the position of Chairman and CEO of Syntex Corporation, which was sold to The Roche Group for $5.3 billion during his tenure.
Mr. Freiman holds a B.S. degree in pharmacy from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy.
Mr. Li (LI Xinzhou) has served as a director of NovaBay since April 10, 2015. Mr. Li is Chairman and Executive Director of China Pioneer Pharma, the exclusive distributor of NovaBay’s NeutroPhase® Skin and Wound Cleanser in China and Southeast Asia, as well as NovaBay’s largest stockholder. Mr. Li previously served as the Board’s Asia-Pacific advisor for over two years. Mr. Li founded China Pioneer Pharma in July 1996, and is responsible for managing its operations and planning, and for formulating the company’s strategies. He has more than eighteen years of experience in the pharmaceutical services industry and has more than twenty years of experience in international trading and management. Prior to China Pioneer Pharma, Mr. Li worked at the Hainan branch of Sumitomo Corporation.
Mr. Li graduated from Jianghan Petroleum Normal School with a diploma in English and studied at the China Europe International Business School.
Ms. Maderis most recently served as President and CEO of BayBio before its merger with California Healthcare Institute (CHI) in December of 2014. Ms. Maderis was previously President and CEO of FivePrime Therapeutics, Inc., a biotechnology company that is focused on the discovery and development of innovative protein and antibody drugs, and prior to that, held general management positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology, a publicly traded division of Genzyme, and corporate vice president of Genzyme Corporation. Ms. Maderis has been a member of several boards, and currently serves on The Mayor’s Biotech Advisory Council of San Francisco, as well as the HBS Healthcare Initiative board.
Ms. Maderis received a B.S. degree in business from the University of California at Berkeley and an M.B.A. from Harvard Business School.
Yonghao Ma (Carl Ma)
Dr. Ma is currently the founder, owner and President of PharmStats, Ltd. (“PharmStats”) since September 1997. PharmStats is a Delaware corporation formed in 1997, specializing in statistical consulting and support for pharmaceutical research and development, registration of pharmaceutical products in the United States and Europe, phase IV post-market research, and health outcomes research. Dr. Ma is particularly experienced in the areas of oncology, the central nervous system, dermatology, pain (acute and chronic) management, multiple sclerosis, and HIV infection. Over the course of his career, Dr. Ma has participated in, or managed, many clinical trials with regard to design, statistical conduct, and regulatory filings in the United States and Europe, including new drug applications. From August 1991 to September 1997, Dr. Ma was an Assistant Professor of Mathematics at Texas State University. Dr. Ma has a Ph.D. in Mathematics from the University of Utah (1991).
Mr. Zavodnick has served as a director of NovaBay since May 2016. Mr. Zavodnick has served as President, International at ZELTIQ since January 2016. Prior to joining ZELTIQ, Mr. Zavodnick served as President and General Manager of North America at Galderma, having worked there from May 2012 to January 2016. From January 2004 to July 2012, Mr. Zavodnick worked at Alcon, eventually serving as the President of Alcon China and Mongolia. Mr. Zavodnick received a bachelor’s degree from Rutgers University and an M.B.A. degree from the University of Texas at Dallas.
Mijia WU (Bob Wu)
Since June 2008, Mr. Wu has been the Managing Director of China Kington, an affiliated entity of China Kington Investment Co. Ltd., which acted as the sole
placement agent for a $6.86 million private placement of NovaBay common stock and warrants to purchase common stock in May 2015. Concurrently, he has served as the Managing Director of Shanghai Ceton Investment Management Co. Ltd. Since October 2013, he has also been the Non-Executive Director of China Pioneer Pharmaceutical Holdings Ltd. (“Pioneer”). Previously, he served as Director at UBS AG, Hong Kong Branch, in 2007 and Vice President of BNP Paribas Hong Kong from 2005 to 2006. He was also the Assistant Vice President at ABN AMRO Bank (China) Co., Ltd. from 2002 to 2005. All told, Mr. Wu brings over 10 years of experience in finance and investment to the Board.
He holds a Master in Business Administration from Manchester Business School, University of Manchester and an Executive Master in Business Administration from Cheung Kong Graduate School of Business.
Xiaoyan LIU (Henry Liu)
Since 2015, Mr. Liu has been the Director of Ant Capital Pty Ltd. (“Ant Capital”), an investment company based in Australia. Prior to founding Ant Capital,
Mr. Liu served as Operations Team Lead of Citic Pacific Mining from 2013 to 2014 and before that, served as Solution Team Lead of ZTE Australia from 2010 to 2013. Mr. Liu was employed by China Telecom from 1996 to 2009, where he was in charge of the company’s operations team. He brings more than 15 years of stock market investment experience and 10 years of leadership experience in the telecommunications industry to the Board.
Mr. Liu received an associate degree of Applied Electrical Technology from University of Changsha, Hunan, China.